Home » Topics » Regulatory » Patents

Patents
RSS

Sato Pharmaceutical patents new HPGDS inhibitors

Jan. 11, 2022

Autobahn Therapeutics discloses thyroid hormone receptor agonists

Jan. 11, 2022

Volastra Therapeutics identifies ENPP1 inhibitors

Jan. 10, 2022

Incyte synthesizes new JAK2 V617F inhibitors

Jan. 10, 2022

Gossamer Bio presents DGKA and/or DGKZ inhibitors

Jan. 10, 2022

The Vanderbilt University divulges new muscarinic M5 receptor antagonists

Jan. 10, 2022

Dana-Farber Cancer Institute patents UCP1 activators

Jan. 10, 2022

BioWorld MedTech Patent Highlights: Week 52

From Current Patent Gazette

Jan. 7, 2022

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Wigen Biomedicine Technology synthesizes new Wee1 inhibitors

Jan. 7, 2022

Chinese researchers describe new GLP-1 receptor agonists

Jan. 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.